Malignant Solid Tumour Clinical Trial
Official title:
Inhibition of Autophagy in Solid Tumors: A Phase I Pharmacokinetic and Pharmacodynamic Study of Hydroxychloroquine in Combination With the HDAC Inhibitor Vorinostat for the Treatment of Patients With Advanced Solid Tumors With an Expansion Study in Advanced Renal and Colorectal Cancer
This study is an open label non randomized study of hydroxychloroquine (HCQ) with histone deacetylase (HDAC) inhibitor Vorinostat in patients with advanced solid tumors to determine the maximum tolerated dose (MTD) and to evaluate the safety and antitumor activity of this drug combination.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01721148 -
A Phase I Multiple Ascending Dose Study of ASLAN002 in Subjects With Advanced or Metastatic Solid Tumours
|
Phase 1 | |
| Completed |
NCT00551096 -
Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT01435096 -
BN80927 in Patients With Advanced Malignant Solid Tumors
|
Phase 1 | |
| Completed |
NCT01951846 -
To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours
|
Phase 1 | |
| Completed |
NCT01325558 -
A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Completed |
NCT01554371 -
Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT01286896 -
Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT01309490 -
Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT00635791 -
Phase I Study of Vorinostat and Sorafenib in Advanced Cancer
|
Phase 1 | |
| Completed |
NCT01376505 -
Vaccine Therapy in Treating Patients With Metastatic Solid Tumors
|
Phase 1 | |
| Completed |
NCT00388427 -
Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies
|
Phase 1 | |
| Completed |
NCT01611857 -
Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach
|
Phase 1/Phase 2 | |
| Completed |
NCT02843204 -
Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT02853903 -
Comparison of Autogenic and Allogenic NK Immunotherapy on the Outcome of Recurrent Solid Tumors
|
Phase 2 | |
| Completed |
NCT01618136 -
An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Terminated |
NCT00801151 -
Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer
|
Phase 1 | |
| Completed |
NCT02786628 -
Assessing Physical Fitness in Cancer Patients With Cardiopulmonary Exercise Testing and Wearable Data Generation
|
||
| Completed |
NCT01184807 -
Phase 1, Dose-escalation Trial of OPB-51602 in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT00969410 -
A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases
|
Phase 1 | |
| Completed |
NCT02857920 -
Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors
|
Phase 1/Phase 2 |